# US 2026/0218215 A1 · Host cells with pat1 knockout for increased specific protein productivity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0218215 A1
- Document ID: US20260218215A1
- Status: Published application
- Kind: A1
- Application number: 19/141,870
- Filed: 2023-12-20
- Published: 2026-07-30
- Earliest claimed: 2022-12-20
- Assignees: Lonza Ltd.
- Applicants: Lonza Ltd
- Inventors: Jennifer STAUDACHER; Brigitte GASSER; Marc FEARY; Louise JONES
- Web page: https://patentgrep.com/patent/US20260218215A1

## CPC

- C12N 15/79: Vectors or expression systems specially adapted for eukaryotic hosts
- C12N 15/815: {for yeasts other than Saccharomyces}
- C07K 14/765: Serum albumin, e.g. HSA
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/67: General methods for enhancing the expression
- C12N 15/907: {in mammalian cells}
- C07K 2317/14: Specific host cells or culture conditions, e.g. components, pH or temperature
- C07K 2317/22: from camelids, e.g. camel, llama or dromedary
- C07K 2317/35: Valency
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

A eukaryotic host cell which is engineered to introduce a recombinant expression cassette expressing a gene of interest (GOI) to produce a protein of interest (POI), and by a genetic modification to control expression of a Pat1 protein.

## Claims

### Claim 1

A eukaryotic host cell which is engineered to introduce a recombinant expression cassette expressing a gene of interest (GOI) to produce a protein of interest (POI), and by a genetic modification to control expression of a Pat1 protein.

### Claim 2 (depends on 1)

The host cell of claim 1, wherein the level of the Pat1 protein is controlled by said genetic modification, and wherein controlling the level of the Pat1 protein increases the POI yield and/or titer.

### Claim at position 3

3-6. (canceled)

### Claim 7 (depends on 1)

The host cell of claim 1, wherein the expression of the Pat1 protein is reduced compared to an endogenous expression thereof.

### Claim 8 (depends on 7)

The host cell of claim 7, wherein said genetic modification comprises a disruption, substitution, deletion or knockout of (i) an endogenous polynucleotide encoding the Pat1 protein, or a part thereof; or (ii) an expression control sequence that controls expression of a polynucleotide encoding the Pat1 protein, wherein the polynucleotide encoding the Pat1 protein is endogenous to the host cell.

### Claim at position 6

9-11. (canceled)

### Claim 12 (depends on 1)

The host cell of claim 1, wherein the expression cassette comprises one or more expression control sequences operably linked to said GOI.

### Claim 13 (depends on 12)

The host cell of claim 12, wherein said one or more expression control sequences comprise a promoter which is an inducible, de-repressible or otherwise regulatable promoter, or a constitutive promoter.

### Claim 14

(canceled)

### Claim 15

(canceled)

### Claim 16 (depends on 1)

The host cell of claim 1, wherein the POI is a therapeutic or diagnostic product.

### Claim 17 (depends on 16)

The host cell of claim 16, wherein the POI is a therapeutic product selected from the group consisting of an antigen-binding protein, an enzyme, a peptide, a protein antibiotic, a toxin fusion protein, a structural protein, a regulatory protein, a protein vaccine antigen, a hormone, a growth factor, a cytokine, and a blood clotting or coagulation factor.

### Claim 18 (depends on 17)

The host cell of claim 17, wherein the antigen-binding protein is an antibody molecule, wherein the antibody molecule is a monoclonal antibody, a full-length antibody, an antibody comprising one or more epitope binding fragments of a full-length antibody, or a bispecific or multi-specific antibody comprising one or more of said fragments, wherein said one or more epitope binding fragments of a full-length antibody are Fab, Fab′, F(ab′)2, Fv, or scFv fragments, or single domain antibodies.

### Claim at position 14

19-21. (canceled)

### Claim 22 (depends on 1)

The host cell of claim 1, wherein the POI is a process enzyme or metabolic enzyme.

### Claim 23 (depends on 1)

The host cell of claim 1, wherein the Pat1 protein is Pat1 comprising SEQ ID NO:1, SEQ ID NO:3, any one of SEQ ID NOs:13 to 17, or any one of SEQ ID NOs:97to 101, or a Pat1 ortholog to any one of the foregoing, which is encoded by a host cell endogenous polynucleotide without said genetic modification to control expression of said Pat1 protein, wherein the host cell endogenous polynucleotide is endogenous to the wild-type host cell.

### Claim 24

(canceled)

### Claim 25

(canceled)

### Claim 26 (depends on 1)

The host cell of claim 1, wherein the host cell is any one of Pichia pastoris, Saccharomyces cerevisiae, Yarrowia lipolytica, Ogataea polymorpha, Schizosaccharomyces pombe, Trichoderma reesei, Kluyveromyces lactis, Aspergillus niger, Homo sapiens, or Cricetulu griseus host cells, wherein the Pichia pastoris is selected from Komagataella phaffii, Komagataella pastoris, and Komagataella pseudopastoris.

### Claim 27 (depends on 1)

The host cell of claim 1, wherein:
a) the host cell is a Komagataella phaffii host cell, and the Pat1 protein comprises at least 90% sequence identity to SEQ ID NO:1;
b) the host cell is a Komagataella pastoris host cell, and the Pat1 protein comprises at least 90% sequence identity to SEQ ID NO:3;
c) the host cell is a Saccharomyces cerevisiae host cell, and the Pat1 protein comprises at least 90% sequence identity to SEQ ID NO:4;
d) the host cell is a Yarrowia lipolytica host cell, and the Pat1 protein comprises at least 90% sequence identity to SEQ ID NO:5;
e) the host cell is an Ogataea polymorpha host cell, and the Pat1 protein comprises at least 90% sequence identity to SEQ ID NO:6;
f) the host cell is a Schizosaccharomyces pombe host cell, and the Pat1 protein comprises at least 90% sequence identity to SEQ ID NO:7;
g) the host cell is a Trichoderma reesei host cell, and the Pat1 protein comprises at least 90% sequence identity to SEQ ID NO:8 h) the host cell is a Kluyveromyces lactis host cell, and the Pat1 protein comprises at least 90% sequence identity to SEQ ID NO:9;
i) the host cell is an Aspergillus niger host cell, and the Pat1 protein comprises at least 90% sequence identity to SEQ ID NO:10,
j) the host cell is a Homo sapiens host cell, and the Pat1 protein comprises at least 90% sequence identity to SEQ ID NO:11 or 12; or
k) the host cell is a Cricetulu griseus host cell, and the Pat1 protein comprises at least 90% sequence identity to any one of SEQ ID NOs: 13 to 17, or any one of SEQ ID NOs:97 to 101.

### Claim 28

(canceled)

### Claim 29 (depends on 1)

The host cell of claim 1, wherein the host cell is a P. pastoris or CHO cell.

### Claim 30 (depends on 1)

A method for producing a host cell of claim 1, comprising genetic engineering of a host cell to (i) introduce said recombinant expression cassette expressing said GOI, and to (ii) control expression of a Pat1 protein.

### Claim at position 24

31-35. (canceled)

### Claim 36 (depends on 30)

The method of claim 30, wherein the genetic engineering comprises knocking out at least one or all copies of a gene encoding the Pat1 protein from the genome of the cell or a regulatory nucleic acid sequence operably linked to the gene encoding the Pat1 protein, by a split-marker cassette method, or by a method using a CRISPR-Cas9 protein in combination with an RNA specific for the gene encoding the Pat1 protein or specific to the regulatory nucleic acid sequence.

### Claim 37

A method of increasing the yield of producing a heterologous protein of interest (POI) in a cell culture of a host cell under carbon source limiting conditions, by engineering the host cell to control expression of a Pat1 protein in the host cell.

### Claim 38 (depends on 37)

The method of claim 37, wherein the carbon-source limiting conditions are characterized by the presence of a growth-limiting amount of a carbon source in the host cell culture, which is up to 1 g/L.

### Claim 39 (depends on 37)

The method of claim 37, wherein the yield is at least 1.2-fold increased compared to the host cell without said genetic modification to control expression of the Pat1 protein.

### Claim at position 29

40-41. (canceled)

### Claim 42 (depends on 37)

The method of claim 37, wherein the expression of the Pat1 protein is reduced compared to an endogenous expression thereof.

### Claim 43 (depends on 42)

The method of claim 42, wherein the engineering comprises knocking out at least one or all copies of a gene encoding the Pat1 protein from the genome of the cell or a regulatory nucleic acid sequence operably linked to the gene encoding the Pat1 protein, by a split-marker cassette method, or by a method using a CRISPR-Cas9 protein in combination with an RNA specific for the gene encoding the Pat1 protein or specific to the regulatory nucleic acid sequence.

### Claim 44 (depends on 37)

The method of claim 37, wherein the host cell is a P. pastoris host cell, wherein the expression of the Pat1 protein is reduced by inactivating expression of the Pat1 protein in the host cell.

### Claim 45

(canceled)

### Claim 46 (depends on 1)

A method for producing a protein of interest (POI) in a host cell culture, by culturing the host cell of claim 1 under conditions to produce said POI.

### Claim 47 (depends on 46)

The method of claim 46, wherein the host cell is cultured in a host cell culture under carbon-source limiting conditions to produce said POI.

### Claim 48 (depends on 46)

The method of claim 46, wherein the carbon-source limiting conditions are characterized by the presence of a growth-limiting amount of a carbon source in the host cell culture, which is up to 1 g/L.

### Claim 49

(canceled)

### Claim 50

(canceled)

### Claim 51

A pat1 knockout eukaryotic host cell producing a protein of interest (POI) at an at least 1.2-fold increased yield and/or titer and/or specific productivity (μg/g cell dry mass (CDM)) per hour and/or volumetric productivity (μg/L per hour) compared to the host cell without said pat1 knockout, wherein:
a) the host cell is a Komagataella phaffli host cell, and the Pat1 protein comprises at least 90% sequence identity to SEQ ID NO:1:
b) the host cell is a Komaataella pastoris host cell, and the Pat1 protein comprises at least 90% sequence identity to SEQ ID NO:3:
c) the host cell is a Saccharomyces cerevisiae host cell, and the Pat1 protein comprises at least 90% sequence identity to SEQ ID NO:4;
d) the host cell is a Yarrowia lipolytica host cell, and the Pat1 protein comprises at least 90% sequence identity to SEQ ID NO:5;
e) the host cell is an Ogataea polymorpha host cell, and the Pat1 protein comprises at least 90% sequence identity to SEQ ID NO:6:
f) the host cell is a Schizosaccharomyces pombe host cell, and the Pat1 protein comprises at least 90% sequence identity to SEQ ID NO:7;
g) the host cell is a Trichoderma reesei host cell, and the Pat1 protein comprises at least 90% sequence identity to SEQ ID NO:8;
h) the host cell is a Kluyveromyces lactis host cell, and the Pat1 protein comprises at least 90% sequence identity to SEQ ID NO:9:
i) the host cell is an Aspergillus niger host cell, and the Pat1 protein comprises at least 90% sequence identity to SEQ ID NO:10;
j) the host cell is a Homo sapiens host cell, and the Pat1 protein comprises at least 90% sequence identity to SEQ ID NO:11 or 12: or
k) the host cell is a Cricetulu griseus host cell, and the Pat1 protein comprises at least 90% sequence identity to any one of SEQ ID NOs:13 to 17, or any one of SEQ ID NOs:97 to 101.

### Claim at position 40

52-61. (canceled)

### Claim 62 (depends on 51)

The pat1 knockout eukaryotic host cell of claim 51, wherein the POI is a therapeutic or diagnostic product.

### Claim 63 (depends on 62)

The pat1 knockout eukaryotic host cell of claim 62, wherein the POI is a therapeutic product selected from the group consisting of an antigen-binding protein, an enzyme, a peptide, a protein antibiotic, a toxin fusion protein, a structural protein, a regulatory protein, a protein vaccine antigen, a hormone, a growth factor, a cytokine, and a blood clotting or coagulation factor.

### Claim 64 (depends on 63)

The pat1 knockout eukaryotic host cell of claim 63, wherein the antigen-binding protein is an antibody molecule, wherein the antibody molecule is a monoclonal antibody, a full-length antibody, an antibody comprising one or more epitope binding fragments of a full-length antibody, or a bispecific or multi-specific antibody comprising one or more of said fragments, wherein said one or more epitope binding fragments of a full-length antibody are Fab, Fab′, F(ab′)2, Fv, or scFv fragments, or single domain antibodies.

### Claim at position 44

65-67. (canceled)

### Claim 68 (depends on 51)

The pat1 knockout eukaryotic host cell of claim 51, wherein the POI is a process enzyme or metabolic enzyme.

### Claim 69 (depends on 13)

The host cell of claim 13, wherein the promoter is any one of SEQ ID NO:38-51, or any one of a CMV, SV40 or PGK promoter.
